Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Date:1/29/2009

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce fourth quarter and full year 2008 financial results after the regular close of markets on Thursday, February 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EST.

Interested participants and investors may access the conference call at 5 p.m. EST by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8627644.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, an audio webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

Amicus' press releases are available at www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lyso
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
2. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
3. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
6. Amicus Therapeutics Opens Research Facility in San Diego
7. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
8. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
9. Amicus Therapeutics Announces First Quarter 2008 Financial Results
10. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...alif., Dec. 2 Peregrine ...ted completion of patient enrollment in a dose con...atients with relapsed glioblastoma multiforme (GBM...a targeted monoclonal antibody linked to a radiois... for GBM. Cotara specifically targets cells at th...
(Date:12/2/2009)...D, The Netherlands, December 2 Pep...gy company focusing on protein mimicking,technolog...announced that it,has appointed Wim E.M. Mol, Ph.D...ol will be responsible for all of Pepscans corpora...gic direction of the company. He brings to,Pepscan...
(Date:12/2/2009)...ORE, Dec. 2 S*BIO Pte Ltd today an...inhibitor, SB1518, at The American Society of Hema...rleans. ,, Data will be presented on the clinic...of SB1518 detailing its safety, tolerability and p...dose levels ranging from 100 to 600 mg. These dose...
(Date:12/2/2009)... Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on endoc...e U.S. Food and Drug Administration (FDA) has gran...Akt pathway inhibitor compound, perifosine (KRX-04...iple myeloma. Keryx Biopharmaceuticals, Inc. ("Ker...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...ilestone achieved bringing Enerkem one step closer...d biochemicals to commercially use waste, feeds...m Inc., a leading advanced biofuels and biochemica...rst commercial-scale plant located in Westbury, Qu...uction of its clean conditioned synthesis gas. , C...
...ucted by Novartis to evaluate safety and efficacy ...ination with ribavirin in patients with genotypes ... Human Genome Sciences, Inc. (Nasdaq: HGSI ) to...n a Phase 2b trial that will evaluate the safety a...) administered monthly in combination with ribavir...
...R, Jersey, January 12 , - Reflects Strong Int...f,World,s Leading IP Management Specialist and Leg...ld,s top intellectual property,( http://www.cpaglo... provider,of outsourced legal support services, ha...launch of a new brand worldwide. , Founded in ...
Other Biology Technology:Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 2Enerkem announces first commercial-scale biofuels and biochemicals plant is entering start-up phase 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 2Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 3Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 4Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
(Date:12/2/2009)..., PHILADELPHIA New study results strengthen the ...ong period of time have an increased risk for deve... other risk factors. , "This provides one more ...e," said senior author Michael J. Thun, M.D., M.S....llance research at the American Cancer Society. "C...
(Date:12/2/2009)..., PHILADELPHIA Mexican-American adolescents expo... likely to pick up the habit themselves, and this ...d with smoking initiation, according to new study ...smoking in the United States and highlights the gl...on Framework Convention on Tobacco Control, which ...
(Date:12/2/2009)... WEST LAFAYETTE, Ind. ╤ A Smoky Mountain for...ate may play a role in how forest understories rec...research. , Despite heavy logging in portions of...of trillium plants on the secondary forest floor w...enkins, a Purdue assistant professor of forestry a...
Breaking Biology News(10 mins):Cigarette smoking increases colorectal cancer risk 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Study finds logging effects vary based on a forest's history, climate 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 1Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 2Service Outsourcing Opportunities in Medical Device Market worth US 2426 77 Billion by 2014 6193 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 1SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 2SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 3SciScout LLC Launches SciAnswers com a Science Based Questions and Answers 28Q 26amp 3BA 29 Site with a Social Networking Perspective 14806 4Stemedica President Invited To Lecture At The University Of Oxford 61211 1Stemedica President Invited To Lecture At The University Of Oxford 61211 2Stemedica President Invited To Lecture At The University Of Oxford 61211 3
...enome Research Institute (NHGRI), one of the Natio...veral new sequencing targets including the Norther...ing the stage for completing a quest to sequence t... from each of the major positions along the evolut...ial resource for researchers unraveling the geneti...
... global study has found all forms of tobacco expos...second hand smoke, increase the risk of heart atta...n Teo of the Michael G. DeGroote School of Medicin...ces in Hamilton, is published in this week,s issue...es from 52 countries, they calculated the risk of ...
...nnas contain 70% of the world,s plants and are cri...ernational project involving researchers from the ...the impact of global warming on these sensitive ar...t of a vicious cycle, where global warming causes ...t of carbon in the atmosphere, raising the earth,s...
Other Biology News:NHGRI announces latest sequencing targets 2NHGRI announces latest sequencing targets 3NHGRI announces latest sequencing targets 4NHGRI announces latest sequencing targets 5NHGRI announces latest sequencing targets 6Global study shows all tobacco bad for the heart 2Global study shows all tobacco bad for the heart 3The vicious cycle of rainforest destruction 2
Epi-Grids Colony Grid Templates-24 Squares from EPICENTRE Biotechnologies
Mouse IgG3 EIA Kit from Assay Designs/Stressgen Bioreagents
...ains 200 g of lyophilized peptide derived from the...ds 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptid...s EP1 receptor polyclonal antibody (Catalog No. 10...ibody to block protein-antibody complex formation ...
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
Biology Products: